CoChat

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C

Lietman, Caressa D., Johnson, Melissa L., McCormick, Frank, Lindsay, Colin R. · 2022 · American Society of Clinical Oncology Educational Book

Abstract

Despite the discovery of RAS oncogenes in human tumor DNA 40 years ago, the development of effective targeted therapies directed against RAS has lagged behind those more successful advancements in the field of therapeutic tyrosine kinase inhibitors targeting other oncogenes such as EGFR, ALK, and ROS1. The discoveries that (1) malignant RAS oncogenes differ from their wild-type counterparts by only a single amino acid change and (2) covalent inhibition of the cysteine residue at codon 12 of KRAS G12C in its inactive GDP-bound state resulted in effective inhibition of oncogenic RAS signaling and have catalyzed a dramatic shift in mindset toward KRAS-driven cancers. Although the development of allele-selective KRAS G12C inhibitors has changed a treatment paradigm, the clinical activity of these agents is more modest than tyrosine kinase inhibitors targeting other oncogene-driven cancers. Heterogeneous resistance mechanisms generally result in the restoration of RAS/mitogen-activated protein kinase pathway signaling. Many approaches are being evaluated to overcome this resistance, with many combinatorial clinical trials ongoing. Furthermore, because KRAS G12D and KRAS G12V are more prevalent than KRAS G12C , there remains an unmet need for additional therapeutic strategies for these patients. Thus, our current translational standing could be described as “the end of the beginning,” with additional discovery and research innovation needed to address the enormous disease burden imposed by RAS-mutant cancers. Here, we describe the development of KRAS G12C inhibitors, the challenges of resistance to these inhibitors, strategies to mitigate that resistance, and new approaches being taken to address other RAS-mutant cancers.

Overview

Integrity signals

Registry

Crossref · 10.1200/edbk_351333

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 90 references

Research works printed but not linked: 12

  1. Healy FM, Br J Pharmacol.
  2. Proulx-Rocray F, 2021, J Clin Oncol., 39
  3. Skoulidis F, 2021, J Clin Oncol., 39
  4. Brana I, 2021, J Clin Oncol., 39
  5. Hofmann MH, 2021, Cancer Res., 81
  6. Gort E, 2020, J Clin Oncol., 38
  7. Gandara D, 2021, Mol Cancer Ther., 20
  8. Ramalingam S, 2021, Mol Cancer Ther., 20
  9. Koltun E, 2021, Cancer Res., 81
  10. Krebs MG, 2021, Cancer Res., 81
  11. Ricciuti B, Clin Cancer Res.
  12. Boumelha J, 2022, Cancer Immunol Res., 10

Cited by

See all 47

Metadata

Authors
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R.
Affiliations
  • Sarah Cannon (US)
  • UCSF Helen Diller Family Comprehensive Cancer Center (US)
  • University of Manchester (GB)
Venue
American Society of Clinical Oncology Educational Book
Published
2022-07
Volume
42
Issue
42
Pages
205-217
ISSN
  • 1548-8748 (ISSN-L)
  • 1548-8756
OpenAlex
W4280497507
Cited by
44
References
90
Citations by year
2026: 2 · 2025: 8 · 2024: 23 · 2023: 7 · 2022: 4
FWCI
3.43
Type
journal article
Language
en
Open access
closed
Locations
  • American Society of Clinical Oncology Educational Book (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS G12C inhibitors, KRAS mutation, oncogenic Ras, drug resistance mechanisms, KRAS G12D, KRAS G12V, targeted cancer therapy, combination therapy
MeSH terms
Humans, Mutation, Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Genes, ras, Proto-Oncogene Proteins p21(ras), Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C. https://app.cochat.ai/papers/10.1200/edbk_351333
The paper
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022). More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_351333

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.